Related Experiment Video
Updated: May 16, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Current clinical management of Fanconi anemia
Angela R Smith1, John E Wagner
1University of Minnesota, Division of Pediatric Blood and Marrow Transplantation, 420 Delaware Street SE, MMC 366, Minneapolis, MN 55455, USA. smith719@umn.edu
Abstract:
Fanconi anemia (FA) is a heterogeneous disease characterized by spontaneous chromosomal breaks and abnormal DNA repair. Major clinical problems in FA include congenital abnormalities, endocrinopathies, early onset bone marrow failure and increased risk of myelodysplastic syndrome, acute leukemia and solid tumors. To date, 15 different genes have been shown to cause FA, all of which have some role in DNA double-strand break repair. Very few strict genotype-phenotype associations have been identified and clinical manifestations vary widely from patient to patient, most likely due to modifier genes, environment and chance effects. Hematopoietic stem cell transplantation is the only proven cure for the hematopoietic manifestations of FA and aggressive lifelong surveillance for solid tumors is essential.
Related Concept Videos
Acute Kidney Injury V: Interprofessional Care
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Hemodialysis III: Nursing Management
Acute Kidney Injury VI: Nursing Management
Continuous Renal Replacement Therapy